Cold Hands: Labs, Causes, and Next Steps

What Actually Causes Cold Hands?

Cold hands arise when blood flow to the fingers drops below the level needed to maintain normal skin temperature. That reduction can come from vasospasm, structural arterial narrowing, low cardiac output, hormonal shifts, or systemic illness. The cause shapes both the workup and the treatment, so identifying it precisely matters more than offering a generic "dress warmly" recommendation.

Raynaud Phenomenon

Raynaud phenomenon is the leading cause of episodic cold, color-changing hands. The classic triphasic sequence runs white (vasospasm), blue (deoxygenation), then red (reperfusion). Primary Raynaud has no identifiable underlying disease; secondary Raynaud is driven by connective-tissue disorders, medications, or occupational vibration exposure. A 2019 systematic review in BMJ Open estimated primary Raynaud prevalence at 4.9% in women and 2.1% in men.

Secondary Raynaud demands a more urgent workup. Conditions such as systemic sclerosis, systemic lupus erythematosus, and mixed connective-tissue disease all produce secondary Raynaud as an early finding, sometimes years before other organ involvement appears.

Hypothyroidism

Thyroid hormone controls basal metabolic rate and peripheral vascular tone. When TSH rises above the normal reference range (roughly 0.4 to 4.5 mIU/L at most labs), peripheral vasoconstriction increases and the sensation of cold hands is one of the most patient-reported complaints. The American Thyroid Association notes that cold intolerance is present in approximately 40% of patients with overt hypothyroidism.

Iron-Deficiency Anemia

Reduced hemoglobin cuts the oxygen-carrying capacity of blood. The cardiovascular system compensates by redistributing flow away from the skin toward vital organs, which leaves fingers feeling cold even when ambient temperature is normal. The WHO estimates iron-deficiency anemia affects approximately 1.62 billion people worldwide, making it one of the most prevalent modifiable causes of cold extremities globally.

Peripheral Arterial Disease

Peripheral arterial disease (PAD) reduces perfusion through fixed atherosclerotic stenosis rather than reversible vasospasm. Risk factors include smoking, diabetes, hypertension, and hyperlipidemia. Cold hands from PAD tend to be persistent rather than episodic and are often accompanied by pallor on elevation and dependent rubor. The ankle-brachial index (ABI) is the standard screening tool for lower-extremity PAD; for upper-extremity involvement, duplex ultrasound or wrist-brachial index is used.

Less Common but Clinically Important Causes

Several other conditions warrant consideration when the common causes are excluded:

• Medication-induced vasospasm. Beta-blockers, ergotamine, some chemotherapy agents (especially bleomycin and cisplatin), and amphetamines all reduce peripheral blood flow.
• Thoracic outlet syndrome. Compression of the subclavian artery or brachial plexus at the thoracic outlet causes unilateral cold hand with or without neurological symptoms.
• Hyperviscosity states. Polycythemia vera, cryoglobulinemia, and cold agglutinin disease thicken blood at low temperatures, impeding microvascular flow.
• Low estrogen. Perimenopausal and postmenopausal women lose estrogen-mediated vasodilation. Several cohort studies link estrogen deficiency to increased Raynaud severity and general cold sensitivity.

Which Labs Should Be Ordered First?

The initial lab panel should be targeted, not exhaustive. Ordering every vascular test upfront delays the diagnosis by weeks and increases cost without proportional diagnostic yield. The sequence below reflects both clinical probability and cost-effectiveness.

Tier 1: Order on the First Visit

These four tests cover the three most common treatable causes and take a single blood draw:

| Test | What it screens for | Action threshold | |------|---------------------|-----------------| | TSH | Hypothyroidism / hyperthyroidism | <0.4 or >4.5 mIU/L triggers free T4 reflex | | CBC with differential | Anemia, polycythemia, infection | Hemoglobin <12 g/dL (women) or <13 g/dL (men) | | Comprehensive metabolic panel | Renal disease, electrolyte shifts | Creatinine, glucose, BUN | | Fasting lipid panel | Atherosclerotic risk for PAD | LDL >160 mg/dL in PAD-risk patient |

Tier 2: Order When Tier 1 is Abnormal or Clinical Suspicion Remains High

If TSH is elevated, reflex to free T4 and anti-TPO antibodies to distinguish Hashimoto thyroiditis from other causes. If anemia is confirmed, follow with serum ferritin, serum iron, total iron-binding capacity (TIBC), and a reticulocyte count. Ferritin below 30 ng/mL is highly specific for iron deficiency; levels between 30 and 100 ng/mL require clinical correlation.

Tier 3: Autoimmune and Vascular Panel for Suspected Secondary Raynaud

When the history, nailfold capillaroscopy findings, or Tier 1 results suggest connective-tissue disease, the following tests are added:

• Antinuclear antibody (ANA) with reflex to anti-dsDNA, anti-Sm, anti-Scl-70, anti-centromere, and anti-U1-RNP
• ESR and CRP (markers of systemic inflammation)
• Complement levels (C3, C4) if lupus is suspected
• Cryoglobulins and cold agglutinins if hyperviscosity is a concern
• Serum protein electrophoresis if monoclonal protein disease is on the differential

The ACR/EULAR 2013 classification criteria for systemic sclerosis assign points to features including Raynaud phenomenon, abnormal nailfold capillaries, and disease-specific antibodies. A patient scoring 9 or more points meets the threshold for classification as systemic sclerosis.

Nailfold Capillaroscopy: The Underused Office Tool

Nailfold capillaroscopy is a simple, non-invasive examination performed with an ophthalmoscope or dermatoscope at the bedside. Normal capillaries are thin, evenly spaced loops. In secondary Raynaud related to systemic sclerosis or dermatomyositis, the pattern shows dilated, distorted, or "drop-out" capillaries, a finding that precedes abnormal serology in some patients by years. A 2016 review in Seminars in Arthritis and Rheumatism found that abnormal nailfold capillaroscopy predicts progression from primary to secondary Raynaud with a sensitivity of 80 to 95%.

Hormone-Related Cold Hands: Thyroid and Estrogen

Two hormonal axes, thyroid and estrogen, produce cold hands through distinct mechanisms. Getting both right matters, especially in women between ages 40 and 60, where both conditions frequently overlap.

Thyroid Dysfunction

Overt hypothyroidism (TSH >10 mIU/L with low free T4) is treated with levothyroxine, titrated to bring TSH into the lower half of the reference range (0.5 to 2.5 mIU/L in most symptomatic patients). Subclinical hypothyroidism (TSH 4.5 to 10 mIU/L, normal free T4) presents a more nuanced decision. A 2019 Cochrane review of levothyroxine for subclinical hypothyroidism (N=2,496 participants across 21 trials) found no significant improvement in quality of life or symptom scores compared with placebo. Clinicians treating a 45-year-old woman with cold hands, fatigue, and a TSH of 7.8 mIU/L may still choose a trial of levothyroxine with reassessment at 12 weeks, but the evidence base is weaker than for overt disease.

Estrogen Deficiency

Estrogen promotes nitric-oxide-mediated vasodilation. As estrogen falls during the menopausal transition, that vasodilatory cushion shrinks, and women report cold hands, cold feet, and sometimes paradoxical hot flashes in the same 24-hour period. Menopausal hormone therapy (MHT) with estradiol may improve peripheral vascular tone. The Menopause Society (formerly NAMS) 2022 position statement supports MHT for bothersome vasomotor and peripheral symptoms in appropriate candidates under age 60 or within 10 years of menopause onset.

HealthRX Cold-Hands Hormone Triage Framework (for clinical review):

1. Order TSH first. If TSH >4.5 mIU/L, reflex to free T4. Treat overt hypothyroidism; use shared decision-making for subclinical cases.
2. Ask about menstrual cycle changes in women aged 40 to 60. If perimenopause or menopause is confirmed, consider estradiol level and FSH.
3. If both thyroid and estrogen deficiency are present, treat the thyroid first, wait 8 weeks, then reassess peripheral symptoms before starting MHT.
4. If cold hands persist after hormone normalization, return to the Raynaud and vascular workup.

Raynaud Phenomenon: Diagnosis and Treatment

Diagnosing Primary vs. Secondary

The clinical distinction between primary and secondary Raynaud determines urgency. Features that favor secondary disease include onset after age 40, asymmetric attacks, digital pitting or ulceration, abnormal nailfold capillaries, and a positive ANA. Primary Raynaud typically begins in adolescence or early adulthood, affects both hands symmetrically, and produces no tissue damage.

The 2019 British Society for Rheumatology guidelines recommend that all patients with Raynaud phenomenon have a baseline ANA, full blood count, ESR, and nailfold capillaroscopy to screen for secondary causes.

Pharmacological Treatment

Nifedipine extended-release is the best-studied first-line drug. A Cochrane meta-analysis of calcium channel blockers for Raynaud (N=109 in the nifedipine arm) found a 35% reduction in attack frequency and a 20% reduction in severity scores compared with placebo. The standard starting dose is 30 mg once daily; many patients require 60 mg daily for adequate control.

When nifedipine is poorly tolerated (common side effects include headache and peripheral edema), amlodipine 5 to 10 mg daily is a reasonable alternative. For refractory secondary Raynaud, especially in systemic sclerosis, sildenafil 25 to 100 mg twice daily or intravenous iloprost infusions are used in specialist centers.

Non-Pharmacological Measures

Behavioral modifications reduce attack frequency by 30 to 40% in primary Raynaud when applied consistently:

• Layered glove-wearing in temperatures below 15°C (59°F)
• Keeping core temperature warm (a drop in torso temperature triggers hand vasospasm via sympathetic reflex even before the hands feel cold)
• Avoiding nicotine entirely (smoking reduces digital blood flow by 40% within 10 minutes of a single cigarette in Raynaud patients)
• Stress reduction, because sympathetic activation is a direct vasospasm trigger

When to Worry: Red Flags Requiring Urgent Action

Most cold hands are benign. A few presentations, however, require same-day or next-day evaluation.

Refer urgently (same day or next business day) when you see:

• Digital ulcers or necrosis at fingertips
• Sudden unilateral cold hand with pain at rest (possible acute limb ischemia)
• Absent radial pulse
• Cold hands with systemic features: weight loss, dysphagia, skin tightening, or new Raynaud after age 40
• Cold hands with signs of high-output or low-output cardiac failure

Acute limb ischemia is a vascular emergency. The classic "6 Ps" of pain, pallor, pulselessness, paresthesia, paralysis, and poikilothermia (inability to warm the limb) require immediate vascular surgery consultation; every hour of delay worsens tissue salvage rates.

The American Heart Association/American College of Cardiology 2016 lower-extremity PAD guideline states that critical limb ischemia carries a 1-year amputation risk of 25% and a 1-year mortality of 25% without revascularization.

Treatment Pathways by Underlying Cause

Each identified cause has a specific treatment target and timeline for reassessment. Generic cold-hands advice misses that specificity.

Iron-Deficiency Anemia

Oral ferrous sulfate 325 mg three times daily (providing 195 mg elemental iron per day) is standard first-line therapy. Reticulocyte count should rise within 7 to 10 days of starting treatment, and hemoglobin should increase by at least 1 g/dL within 4 weeks. If it does not, re-examine adherence and GI absorption, and consider intravenous iron (ferric carboxymaltose or iron sucrose). Treat for 3 months after hemoglobin normalizes to replenish stores. Cold hands typically improve once hemoglobin exceeds 11 g/dL.

Hypothyroidism

Levothyroxine is dosed by weight: approximately 1.6 mcg/kg/day for full replacement in primary hypothyroidism. Recheck TSH 6 to 8 weeks after starting or changing the dose. Cold-hand symptoms generally improve within 4 to 6 weeks of achieving a euthyroid state, though full peripheral vascular normalization can take 3 to 6 months.

PAD and Vascular Disease

Smoking cessation is the single most effective intervention for PAD progression. Supervised exercise training for 30 to 45 minutes at least three times per week improves walking distance and may improve upper-extremity perfusion in PAD patients. Antiplatelet therapy (aspirin 81 mg daily or clopidogrel 75 mg daily) reduces cardiovascular event risk. Revascularization is considered when symptoms are severe or tissue loss is threatened.

Monitoring and Follow-Up: A Practical Schedule

After labs are drawn and initial treatment starts, a structured follow-up prevents missed diagnoses and treatment failures.

| Timepoint | What to check | |-----------|--------------| | 4 to 6 weeks | TSH (if starting levothyroxine), CBC (if treating iron deficiency), symptom diary for Raynaud attack frequency | | 3 months | Full repeat panel if initial labs were borderline; ANA titer if new symptoms of connective-tissue disease appear | | 6 months | Reassess Raynaud medication efficacy; adjust nifedipine dose or switch to amlodipine if inadequate response | | Annually | Lipid panel, blood pressure, glucose for PAD risk stratification; thyroid function if on levothyroxine |

Patients with confirmed secondary Raynaud and a positive ANA or abnormal capillaroscopy should be seen by rheumatology at least once yearly, as systemic sclerosis can progress from limited to diffuse disease over a 3-to-7-year window in roughly 20% of cases. A longitudinal cohort study by Koenig et al. (2008, N=3,656) found that anti-Scl-70 antibody positivity carries a positive predictive value of 60% for developing systemic sclerosis within 5 years.

Special Populations

Adolescents and Young Adults

Primary Raynaud peaks in females aged 15 to 30. Labs are often normal. The workup should still include ANA and CBC to exclude early-onset lupus, which can first present with Raynaud in this age group. Nifedipine can be used from age 18 onward; behavioral strategies are first-line for younger adolescents.

Older Adults

In patients over 60 with new-onset cold hands, PAD and hypothyroidism take precedence in the differential. The threshold to image the upper-extremity arteries with duplex ultrasound is lower in this group because atherosclerotic disease is more prevalent and symptoms may be the first sign of subclinical cardiovascular disease.

Pregnant Women

Raynaud can worsen or improve in pregnancy. Nifedipine is generally considered compatible with pregnancy in the second and third trimesters based on its established use as a tocolytic and antihypertensive. ACE inhibitors and ARBs are contraindicated. Levothyroxine dose requirements rise by approximately 25 to 30% in pregnancy due to increased thyroid-binding globulin; TSH should be checked every 4 weeks through the first trimester.